While studies of the adaptor SH3BP2 have implicated a role in receptor-mediated signaling in mast cells and lymphocytes, they have failed to identify its function or explain why SH3BP2 missense mutations cause bone loss and inflammation in patients with cherubism. We demonstrate that Sh3bp2 ''cherubism'' mice exhibit trabecular bone loss, TNF-a-dependent systemic inflammation, and cortical bone erosion. The mutant phenotype is lymphocyte independent and can be transferred to mice carrying wild-type Sh3bp2 alleles through mutant fetal liver cells. Mutant myeloid cells show increased responses to M-CSF and RANKL stimulation, and, through mechanisms of increased ERK 1/2 and SYK phosphorylation/activation, they form macrophages that express high levels of TNF-a and osteoclasts that are unusually large. M-CSF and RANKL stimulation of myeloid cells that overexpress wild-type SH3BP2 results in similar large osteoclasts. This indicates that the mutant phenotype reflects gain of SH3BP2 function and suggests that SH3BP2 is a critical regulator of myeloid cell responses to M-CSF and RANKL stimulation.
INTRODUCTION
Much progress has been made in characterizing cytokines that regulate formation of multinucleated bone-resorbing cells (osteoclasts) from mononuclear myeloid progenitors Tanaka et al., 2005) . Much is also known about downstream signaling pathways and transcription factors (Mocsai et al., 2004; Takayanagi et al., 2002) . Many of these pathways are important for regulation of immune cells and other myeloid-derived cells and provide a basis for understanding how pathological bone loss is associated with inflammation in rheumatic diseases (Humphrey et al., 2005; Jimi and Ghosh, 2005; Xing et al., 2005) . However, except for studies of SHIP phosphatase (Takeshita et al., 2002) , little is known about mechanisms that regulate responses of myeloid progenitors to macrophage-and osteoclast-inducing signals.
Cherubism is a dominantly inherited syndrome characterized by excessive bone resorption in the jaws and accumulation of inflammatory/fibrous tissue in the lower face. The pathological facial changes appear 2-4 years after birth and regress after puberty. The association between osteoclast-mediated bone resorption and inflammation suggests an activation of processes controlling differentiation of osteoclasts and inflammatory cells. The disorder was mapped to chromosome 4p, and we identified amino acid missense mutations in the SH3-binding protein SH3BP2 in several cherubism families (Ueki et al., 2001) . Since the SH3BP2 gene is located within a region that frequently is deleted in individuals with Wolf-Hirschhorn syndrome and since patients with this syndrome do not have cherubism (Zollino et al., 2000) , it is unlikely that the missense mutations in SH3BP2 represent loss-of-function mutations (Ueki et al., 2001) .
SH3BP2 was initially identified in a screen for proteins that bind to the SH3 domain of the tyrosine kinase c-Abl (Ren et al., 1993) . Subsequently, it was also identified as a SYK kinase, VAV, and as a 14-3-3 interacting protein (Deckert et al., 1998; Foucault et al., 2003 Foucault et al., , 2005 . Interactions between SH3BP2 and a range of other proteins, including ZAP70, Lyn kinase, PLCg, and LAT, have also been described (Jevremovic et al., 2001; Maeno et al., 2003; Qu et al., 2005; Sada et al., 2002) . The binding of SH3BP2 to several of these proteins requires phosphorylation of tyrosine and serine residues. SYK can phosphorylate tyrosyl residues Y174, Y183, and Y446 (in the mouse protein) within SH3BP2, and phosphorylation of at least one of these residues (Y446) has been suggested to be critical for the ability of SH3BP2 to stimulate SYK tyrosine phosphorylation (Maeno et al., 2003) . Interaction of SH3BP2 with 14-3-3 proteins requires phosphorylation of S225 and S277 (in the mouse protein) in SH3BP2 (Foucault et al., 2003) . The function of SH3BP2 is not defined, but studies of T-and B-lymphoid cells suggest that SH3BP2 may act as stimulator of NFAT-mediated transcription and that this stimulatory activity is negatively regulated by interaction of SH3BP2 with 14-3-3 proteins (Deckert et al., 1998; Foucault et al., 2003) . A recent study of SH3BP2-deficient T and B cells suggests that SH3BP2 is particularly important for signaling in B cells (de la Fuente et al., 2006) .
To obtain insights into SH3BP2 function, we introduced the most common mutation found in cherubism, a prolineto-arginine substitution (P418R in humans; P416R in mice), into the mouse Sh3bp2 gene. Mutant mice are osteoporotic with increased numbers of osteoclasts in bone. In addition, homozygotes have massive infiltration of macrophages into skeletal elements and internal organs. The inflammatory component can be rescued by eliminating TNF-a expression, and all aspects of the phenotype can be transferred through transfer of mutant fetal liver cells into recipients carrying wild-type Sh3bp2 alleles. The studies demonstrate that the adaptor SH3BP2 regulates the bone marrow (BM) monocyte responses to macrophage and osteoclast differentiation signals downstream of the receptors for macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-kB ligand (RANKL) through mechanisms that involve control of ERK 1/2 and SYK kinase activities.
RESULTS

Mouse Model for Cherubism
Embryonic stem cells were electroporated with a targeting construct-encoding mutant SH3BP2 and used to generate chimeras (Figures S1A and S1B). Mice with germline transmission of the targeted allele were crossed with a CMV-cre mouse to excise the Neo cassette (Figures S1A and S1C). Sequencing of cDNA synthesized with mRNA from spleens of heterozygous knockin (KI) animals confirmed heterozygosity for the P416R missense mutation ( Figure S1D ). The mutation did not affect SH3BP2 protein expression in osteoclastic progenitors, in mature osteoclasts generated in vitro by stimulation of BM cells with M-CSF and RANKL, or in spleen cells ( Figure S1E ). Mutant animals were born in the expected Mendelian ratio. Heterozygotes showed no abnormalities by visual inspection and had a normal life span. However, homozygotes showed loss of survival with age ( Figure S3A ).
Bone Loss in SH3BP2 Mutants
MicroCT of calvarial and jaw bones in 10-week-old wildtype and mutant littermates demonstrated reduced bone volume in calvaria, loss of bone around teeth, and reduced cortical bone thickness in jaws in homozygotes but not in heterozygotes ( Figures 1A and 1B) . Histology showed no difference between wild-type and heterozygous mice (data not shown). In contrast, sections of homozygous jaws showed large numbers of osteoclasts positive for tartrate-resistant acid phosphatase (TRAP) along bone surfaces ( Figure 2A) . In long bones, microCT demonstrated bone loss in both heterozygotes and homozygotes. Three-dimensional reconstruction of trabecular bone showed reduced trabecular bone volume and reduced number of trabeculae ( Figures 1C and 1D) . However, only a small change was seen in trabecular thickness ( Figure 1D ).
Homozygous limb bones such as femoral bones showed pitting of the cortical surface, particularly at the distal end ( Figure 1C ). Histomorphometric analyses of femoral trabecular bone from 10-week-old animals confirmed loss of bone in both hetero-and homozygotes. The fraction of the total perimeter of bone profiles occupied by osteoclasts and the number of osteoclasts were increased ( Figure 1E ). The fraction of total perimeter of bone profiles occupied by osteoblasts was increased as well ( Figure 1E ), suggesting that bone loss in mutant mice is associated with increased osteoclast and osteoblast activities.
P416R Mutation in SH3BP2 Causes Enhanced Osteoclast Differentiation
Increased osteoclast numbers, particularly in homozygotes (Figure 2A ), led us to examine differentiation of osteoclastic progenitors from mutant and wild-type animals to osteoclasts. When incubated with M-CSF and RANKL, mutant BM cells differentiated into exceptionally large osteoclasts even at concentrations of RANKL (10 ng/ml) that were insufficient to induce osteoclastic differentiation in wild-type cultures ( Figure 2B ). Not only was the number of osteoclasts higher in mutant cultures, but the number of nuclei per osteoclast was also much higher ( Figures  2C and 2D) . Interestingly, the level of TRAP in conditioned media was not different between heterozygous and homozygous cultures ( Figure 2E ), and serum concentrations of TRAP were elevated in hetero-and homozygotes ( Figure 2F ). The resorptive activity of mutant osteoclasts on dentin slices was elevated ( Figure 2B ). No differences were seen in serum calcium or phosphate levels between the three groups of mice (data not shown). As is consistent with enhanced response to RANKL in mutant BM cells and with formation of unusually large osteoclasts, transcripts known to be strongly expressed in osteoclasts (Takayanagi et al., 2002) were elevated in heterozygous mutant cells after RANKL stimulation ( Figure S2 ).
Systemic Inflammation in Homozygotes
Heterozygous mutants did not show swelling of facial soft tissues and enlargement of lymph nodes as seen in patients with cherubism (Tiziani et al., 1999) , but homozygotes developed swollen eyelids starting about 6 weeks after birth. Swelling of facial features remained in the few homozygotes surviving until 30 weeks ( Figures S3B and  S3C ). Soft-tissue swelling was caused by the presence of inflammatory lesions. Such lesions were present in cortical regions of long bones ( Figure 3A ) and in maxilla, palate, and mandible of homozygotes ( Figures 3B and 3C ). Eyelids were significantly thickened ( Figure 3D ), and the tissues contained macrophages positive for markers F4/80 and CD11b ( Figures 3A, 3C , and 3D). The infiltrates developed postnatally.
In some mice, similar infiltrates filled the synovial space of large joints and penetrated through articular cartilage and underlying bone into BM ( Figure 3E ). Bone-associated infiltrates contained multinucleated TRAP-positive cells ( Figure 3F ) similar to those typically seen in biopsies of human cherubism lesions. X-rays of homozygous bones showed cystic lesions ( Figure 3G ) similar to those seen on X-rays of jaws from patients with cherubism. Macrophage-rich infiltrates containing TRAP-positive cells and areas of fibrosis ( Figure S4) were not limited to craniofacial and limb bones and associated muscles and soft tissues. Inflammatory lesions with F4/80-and CD11b-positive cells were seen in skin and major internal organs, including liver, lung, and stomach ( Figures 4A and 4B) . The inflammation first started in the liver and lungs at 1 week as small foci containing neutrophils and macrophages; at 2 weeks, we observed evidence of mild gastritis and more severe lung and liver inflammation. At 7 weeks, the process appeared in the spine (data not shown). No evidence of bacterial or fungal infection was seen (data not shown).
Increased Levels of TNF-a in Homozygotes Next, we measured TNF-a serum levels. TNF-a could not be detected in sera of wild-type and heterozygous mutants, but homozygous sera contained TNF-a levels ranging from 200 to 700 pg/ml ( Figure 4C ). Furthermore, FACS analysis of F4/80-gated peritoneal macrophages isolated from 10-week-old mice demonstrated dramatic increase in the proportion of TNF-a-expressing cells in homozygous mutants ( Figure 4D ). Increased production of TNF-a by mutant macrophages was also evident when peritoneal macrophages were cultured as adherent cells ( Figure 4E ). Under these conditions, only low levels of TNF-a could be detected in culture supernatants of heterozygous cells after 16 hr. However, after 48 hr, the same high levels of TNF-a were detected in both heteroand homozygous cultures. To find out whether increased production of TNF-a was the result of transcriptional or posttranscriptional mechanisms, we measured TNF-a transcript levels by real-time PCR in BM-derived, M-CSF-dependent macrophages. Following incubation in M-CSF-free media, restimulation of M-CSF-dependent macrophages with M-CSF led to a large increase in TNF-a transcripts in mutant cells ( Figure 4F ). This increase could be inhibited by MEK inhibitor U0126. The inhibitory effect of U0126 was also seen in assays of TNF-a protein in culture supernatants ( Figure 4G ), suggesting that the enhanced production of TNF-a in mutant cells is based on a transcriptional mechanism. To identify which signaling pathway downstream of the M-CSF receptor is mediating the enhanced TNF-a transcription in mutant BM cells, we compared the effects of U0126 and an NF-kB inhibitor, a cell-permeable NEMO-binding domain peptide, on TNF-a protein levels in culture media of M-CSF-dependent, BM-derived macrophages. While U0126 completely inhibited TNF-a production in mutant cells, the NEMObinding domain peptide had a small stimulatory effect ( Figure 4H ). The NEMO-binding domain peptide has been shown to inhibit NF-kB signaling in mouse BM-derived osteoclast progenitors and to block osteoclast formation (Jimi et al., 2004) ; control experiments (data not shown) showed that at the concentration used for the TNF-a experiment, the peptide completely inhibited M-CSF-and RANKL-induced formation of osteoclasts in wild-type and mutant marrow cultures. As expected (Jimi et al., 2004 ), a mutant peptide had no activity (data not shown). Therefore, signaling through NF-kB does not contribute to increased TNF-a production by mutant macrophages.
P416R Mutation Enhances M-CSF-Dependent ERK 1/2 Phosphorylation
The above results indicate that the cherubism mutation in SH3BP2 enhances the response of macrophages to M-CSF by affecting a U0126-sensitive pathway regulating TNF-a transcription. To better define signaling steps affected by mutant SH3BP2, BM cells were incubated with M-CSF, starved with 0.1% FBS, and restimulated with M-CSF. No difference in the total levels and degree of phosphorylation of several signaling components was seen when comparing wild-type and heterozygous mutant cells ( Figure 5A ). In contrast, homozygous cells showed increased levels as well as sustained phosphorylation of ERK 1/2 and increased levels of p38 and IkBa ( Figure 5A ). Increased and sustained levels of phosphorylated ERK 1/2 in homozygous mutant cells were also seen when BM cells were grown with M-CSF, starved with 1 ng/ml M-CSF, and then stimulated with RANKL ( Figure 5B ). High levels of ERK 1/2 phosphorylation were seen even after 6 hr in the presence of only 1 ng/ml of M-CSF, indicating that homozygosity for the cherubism mutation increases the response of myeloid cells to M-CSF.
P416R Mutation Causes Gain of SH3BP2 Function and Affects a SYK-Kinase-Dependent
Step Next we determined expression and phosphorylation levels of intracellular signaling components in differentiating osteoclasts. Cell extracts were prepared at different time points following addition of RANKL to cultures of BM-derived cells that had been ''primed'' by incubation with M-CSF. No significant differences were seen between wild-type and mutant cells either at protein or phosphorylation levels for a number of signaling intermediates and transcription factors, except that the level of phosphorylation at SYK Y346 was increased in both heterozygous and homozygous cells compared with wild-type cells ( Figure 5C ). No differences were seen with antibodies against SYK phosphotyrosines 317 and 519/520 or against SYK protein. Overexpression of both wild-type and mutant SH3BP2 in wild-type, BM-derived osteoclastic progenitors combined with stimulation with M-CSF and RANKL resulted in enhanced levels of SYK Y346 phosphorylation ( Figure 5D ) as well as the formation of osteoclasts with large numbers of nuclei per osteoclast ( Figure 5E ) compared to control cells infected with viruscontaining empty vector. Since overexpression of wildtype SH3BP2 in M-CSF-and RANKL-stimulated myeloid cell cultures results in enhanced SYK phosphorylation and osteoclastogenesis similar to what is seen with M-CSF-and RANKL-stimulated heterozygous and homozygous mutant myeloid cells ( Figures 5C-5E ), the results suggest that the P416R mutation is indeed a gain-offunction mutation.
To find out whether the increased phosphorylation at Y346 is associated with increased SYK kinase activity, we examined the effects of inhibiting SYK activity in differentiating osteoclasts. Addition of a kinase inhibitor at a concentration of 10 mM reduced the number of TRAPpositive multinucleated cells in wild-type marrow cultures to 4%. In contrast, it was reduced to 36% in heterozygous cultures ( Figures 5F and 5G ). This suggests that heterozygous cells have higher levels of SYK activity than wild-type cells. Enlarged Lymph Nodes and Increased Levels of CD11b-Positive Cells in Homozygous Spleen and BM Enlarged cervical lymph nodes are a feature of human cherubism (Tiziani et al., 1999) . In mutant mice, no significant enlargement of lymph nodes was observed in heterozygotes. However, lymph nodes were noticeably larger in homozygotes, and histological analysis demonstrated increased medullary regions of lymph nodes and red pulp in spleen ( Figure 6A ). These regions were strongly positive with F4/80 and CD11b staining ( Figure 6B ). FACS analysis of lymph node cells demonstrated a higher proportion of B cells in mutant nodes. Wild-type lymphocytes contained 24.9% CD19-positive cells compared with 48.8% CD19-positive cells from homozygotes. In contrast, no significant difference was found between wild-type and heterozygous cell populations. FACS analysis of myeloid-gated spleen cells from 6-week-old animals showed 56.6% CD11b-positive cells in homozygotes compared to 35.8% CD11b-positive cells in wild-type mice. FACS analysis of BM from homozygotes also demonstrated increased proportions of CD11b-positive cells, but no difference was seen when comparing heterozygous and wild-type marrow (Figure 6C) . No difference was seen in CD4/CD8 T cell subpopulations in thymus between wild-type and homozygous animals (data not shown).
Since SH3BP2 has been implicated as a positive regulatory adaptor in T cells (Deckert et al., 1998) , B cells (Foucault et al., 2005) , and NK cells (Jevremovic et al., 2001) and because lymphocytes are known to produce factors that induce osteoclastic differentiation and promote inflammation (Nathan, 2002) , the above results raised the possibility that the phenotype in mutant mice may, at least in part, be caused by SH3BP2-dependent abnormal lymphocyte signaling. To examine this possibility, SH3BP2 mutant mice were crossed with RAG1-deficient mice. Mice that were homozygous for the Sh3bp2 mutant allele and null for Rag1 exhibited no improvement in the degree of bone loss when compared with SH3BP2 mutants (Figure 6D) . Furthermore, BM cells stimulated with M-CSF and RANKL showed enhanced formation of large osteoclasts similar to that in marrow cultures from mice carrying only mutant Sh3bp2 alleles ( Figure 6D ). Also, double mutants contained the same macrophage-rich inflammatory infiltrates in internal organs and periosteal regions as were seen in homozygous SH3BP2 single mutants ( Figure 6E ). Finally, double mutants contained elevated serum levels of TNF-a ( Figure 6F ).
Cherubism Is a TNF-a-Dependent Hematopoietic Disorder
To determine the contribution of enhanced M-CSF-mediated signaling to the Sh3bp2 mutant phenotype in vivo, we crossed Sh3bp2 mutants with op/op mice lacking M-CSF. In KI/KI op/op mice, cortical bone resorption and inflammation of the stomach mucosa were practically eliminated ( Figure 6G ), and inflammation of the liver was greatly reduced ( Figure 6H ). However, serum TNF-a levels were still higher than in wild-type mice at 10 weeks ( Figure 6I ), and macrophage numbers were still increased in lymph nodes ( Figure 6G ). To determine whether TNF-a is crucial for the homozygous phenotype, we crossed Sh3bp2 mutants with Tnf-a null mice. Absence of TNF-a resulted in rescue of lymph node abnormalities and systemic inflammation, and it prevented trabecular and cortical bone loss ( Figures 7A and  7B) . However, BM cells from double mutants showed the same enhanced response to M-CSF and RANKL stimulation as heterozygous and homozygous SH3BP2 mutant cultures did ( Figure 7C) .
The enhanced BM cell responses to cytokines that stimulate differentiation to osteoclasts as well as the large numbers of macrophages in skeletal elements and internal organs of homozygotes suggest that cherubism is a hematopoietic disorder. To find out whether this is indeed the case, we transplanted fetal liver cells from wild-type and Sh3bp2 mutant mice into Rag1 null recipients. Eight weeks after injection of fetal liver cells, the recipients receiving liver cells from homozygous Sh3bp2 mutants had high serum levels of TNF-a ( Figure 7D ), exhibited severe osteoporosis ( Figure 7E ), showed formation of abnormally large TRAP-positive osteoclasts in BM cultures stimulated by M-CSF and RANKL ( Figure 7E ), had macrophage-rich infiltrates in internal organs, and showed abnormal lymph nodes similar to those seen in homozygous Sh3bp2 mutant mice ( Figure 7F ). In contrast, TNF-a could not be detected in sera from recipients receiving fetal liver cells from wild-type or heterozygous Sh3bp2 mutant mice ( Figure 7D ), and macrophage-rich cellular infiltrates were not seen. (Figures 5D and 5E ). The effect of the SH3BP2 mutation is therefore a gain-of-function effect. In SH3BP2-deficient mice, only subtle impairment of several B cell processes has been noted (de la Fuente et al., 2006) . Therefore, SH3BP2 is unlikely to be important for setting the basic response threshold to incoming signals in wild-type myeloid cells but may serve to enhance responses under conditions of increased macrophage and osteoclast differentiation.
SH3BP2 and SYK Kinase
How mutant SH3BP2 causes enhanced phosphorylation of SYK Y346 is not clear. SH3BP2 can bind to SYK via its C-terminal SH2 domain, and the two proteins can cooperatively activate NFAT activity in T cells (Deckert et al., 1998) . Furthermore, it has been reported that SH3BP2 can stimulate NFAT-reporter activity in B cells in cooperation with the SYK kinase substrate VAV (Foucault et al., 2005) . Thus, SH3BP2 may function within a SYK-containing complex in osteoclastic progenitors, and cherubism mutations, which are all located in a small region upstream of the SH2 domain (Ueki et al., 2001) , may enhance the ability of SH3BP2 to stimulate phosphorylation of SYK Y346. In preliminary experiments (data not shown), we have found that, when overexpressed with SYK in 293T cells, SH3BP2 can be immunoisolated as a component of a SYK-containing complex. Further studies are needed to determine the molecular composition of this complex and the mechanism by which SH3BP2 regulates phosphorylation of SYK Y346. The similarity between heterozygous and homozygous osteoclast cultures ( Figure 2B ) combined with enhanced SYK Y346 phosphorylation ( Figure 5C ) and evidence of increased SYK activity ( Figure 5G ) suggests that enhanced osteoclastogenesis in cherubism is primarily an effect of SYK activation ( Figure 7G ). This is consistent both with reports that SYK-deficient, BM-derived cells exhibit impaired multinucleation and spreading in the presence of M-CSF and RANKL (Faccio et al., 2003; Mocsai et al., 2004) as well as with the role of SYK kinase as an upstream regulator of the guanine nucleotide-exchange protein VAV3 in osteoclasts (Faccio et al., 2005) . Phosphorylation of SYK at Y342 and Y346 generates a docking site for PLCg and VAV in B cells, and this interaction with PLCg allows SYK to stimulate PI3K-independent Ca 2+ signaling and activation of NFAT (Deckert et al., 1996; Hong et al., 2002; Law et al., 1996) . Given the role of NFATc1 in osteoclastogenesis (Takayanagi et al., 2002) , one may therefore expect enhanced levels of transcripts of several NFAT target genes in mutant osteoclasts consistent with the high levels of transcripts seen in heterozygous osteoclast cultures ( Figure S2 ).
SH3BP2 and Macrophage Activation
The enhanced response to osteoclast-inducing signals in vitro is not significantly different with myeloid cells from heterozygous and homozygous mice. However, the in vivo phenotypes are dramatically different. This in vivo difference is clearly driven by increased expression of TNF-a since high serum levels of TNF-a are only seen in homozygous mutants ( Figure 4C) , and the loss of cortical bone, inflammatory tissue infiltration, and lymph node abnormalities can be eliminated by crossing cherubism mice with TNF-a-deficient mice ( Figures 7A and 7B ). TNF-a induces RANKL expression in BM stromal cells and stimulates formation of CD11b-positive osteoclastic progenitors (Kitaura et al., 2005; Yao et al., 2006) . Activation of ERK kinase is known to result in induction of TNFa (Dumitru et al., 2000) . Sustained phosphorylation of ERK 1/2 in mutant SH3BP2 cells suggests that induction of TNF-a may be a consequence of enhanced ERK 1/2 signaling ( Figure 7G ). Since TNF-a stimulation can also result in ERK 1/2 activation (Eliopoulos et al., 2006) , both high protein levels of ERK 1/2 and sustained phosphorylation in homozygous marrow cells exposed to M-CSF are likely maintained through a positive autocrine feedback loop. The enhanced production of TNF-a in M-CSF-stimulated myeloid cells is associated with increased levels of TNFa transcripts. The TNF-a gene promoter is known to contain several NF-kB-like motifs, and these are thought to play a prominent role in TNF-a transcription (Shakhov et al., 1990) in primary macrophages. However, a cell-permeable NEMO-binding domain peptide did not inhibit TNF-a production in wild-type and mutant BM cells. In contrast, the MEK inhibitor U0126 had a dramatic effect. Therefore, we conclude that enhanced TNF-a transcription and protein production in mutant cells are primarily consequences of enhanced signaling through a U0126-sensitive pathway; this is consistent with sustained phosphorylation of ERK 1/2 in mutant cells (Figures 5A and 5B) .
The basis for ERK 1/2 activation in homozygous mutant cells is not known. Since SH3BP2 can interact with 14-3-3 proteins, which are known to bind to the kinase suppressor of Ras (Kolch, 2005) , we have considered the possibility that the cherubism mutation may affect the binding of SH3BP2 to 14-3-3 proteins, resulting in enhanced ERK 1/2 activation. In fact, Miah et al. (2004) reported that mutant SH3BP2 fails to bind to 14-3-3 proteins in COS-7 cells. However, in preliminary experiments, we have found no difference in the interaction between wild-type and mutant SH3BP2 and 14-3-3t in 293T cells (data not shown).
Cherubism Is a Myeloid Cell-Dependent Disorder
The results of fetal liver cell transplantation and the crosses of Sh3bp2 homozygous mutants with Rag1 À/À mice indicate that the cherubism phenotype is primarily a consequence of abnormal myeloid cell function. At present, we cannot rule out the possibility that the SH3BP2 mutation has a direct effect on osteoblasts; nevertheless, the net effect is loss of bone in both heterozygous and homozygous mutants. The effects of TNF-a in homozygotes are consistent with what is known about this cytokine in the context of other forms of inflammatory bone loss in humans and mice. At low concentrations, TNF-a stimulates M-CSF production by BM stromal cells, and this in turn results in an increase in osteoclastic progenitors in BM (Kitaura et al., 2005) . This is consistent with our finding of increased numbers of CD11b-positive cells in homozygous marrow. Reduced TNF-a serum levels and reduced inflammation in KI/KI mutants following crossing with op/op mice are consistent with the role of M-CSF as inducer of TNF-a in macrophages (Chitu and Stanley, 2005) and with the finding that injection of antibodies against the M-CSF receptor prevents TNF-a-induced osteolysis in mice (Kitaura et al., 2005) . Interestingly, macrophage numbers in lymph nodes were not significantly reduced in KI/KI op/op mice. Also, although TNF-a serum levels were reduced in double mutants, they were still higher than in wild-type mice, and infiltration of macrophages into liver was reduced but not eliminated ( Figures 6H and 6I) . Thus, M-CSF-independent pathways of macrophage differentiation and TNF-a production exist. This is consistent with what is known about lymph node macrophages and postnatal BM recovery of macrophages in op/op mice (Cecchini et al., 1994; Niida et al., 2005) .
To what extent do the abnormalities in mice reflect what happens in humans with cherubism? The human disease starts after birth and results in jaw bone loss as well as soft tissue inflammation/swelling. However, in spite of differences in the disease process in humans and mice, we suggest that the underlying mechanisms are quite similar. Heterozygous cherubism mutations in humans may well result in increased osteoclastogenesis that is partially compensated for by increased osteoblast activity as in mice. The postnatal inflammatory bone loss in jaws may be due to local induction of the process that in homozygous mutant mice appears as systemic TNF-a-driven osteolysis and macrophage infiltration. Once initiated, the process may continue to recruit BM-derived monocytes into the jaws. If correct, the results of this study suggest that anti-TNF-a therapy, which is currently in use for other disorders of inflammatory bone loss such as rheumatoid arthritis (Smolen and Steiner, 2003) , may well be effective in treatment of cherubism.
EXPERIMENTAL PROCEDURES
Mice
To introduce a proline-to-arginine (P416R) mutation into exon 9 of murine Sh3bp2, a targeting construct was made and electroporated into embryonic stem (ES) cells (J1; for details, see Supplemental Data). After screening, four selected ES clones were used for generation of chimeras. After confirmation of germline transmission, mice were crossed with a cre-deleter strain to remove the Neo cassette in the Sh3bp2 gene. All animals in the study were housed in pathogenfree facilities and monitored carefully.
For genotyping, PCR with primers from within intron 8 of the Sh3bp2 gene was used. For sequencing, the Sh3bp2 gene mRNA was isolated from spleens of 10-week-old animals. Immunohistochemistry Tissues were quickly frozen in OCT compound (Sakura, Japan) in an ethanol/dry ice bath. Six micrometer sections were cut (CM3000, Leica Instruments, Nussloch, Germany) and dried at room temperature on Superfrost Plus slides. Just before staining, sections were fixed with acetone for 10 min. Vectastain Elite ABC kit (Vector Laboratories Inc., Burlingame, CA) was used for HRP-based immunohistochemistry. CD11b (clone: M1/70) and F4/80 (clone: CI: A3-1) antibodies were purchased from BD Biosciences Pharmingen (San Diego, CA) and Caltag (Burlingame, CA), respectively. Negative controls included sections incubated without the primary antibodies.
TRAP 5b and TNF-a ELISA TRAP 5b and TNF-a in serum and culture media were measured with a TRAP assay kit (SBA Sciences, Turku, Finland) and DuoSet ELISA Development kit (R&D, Minneapolis, MN), respectively.
BM Cultures
BM cells from tibia and femur of 6-to 10-week-old mice were flushed out with ice-cold a-MEM containing 10% non-heat-inactivated FBS and penicillin/streptomycin. Cell suspension was filtered through a 70 mm nylon cell strainer (BD Falcon, Bedford, MA); red blood cells were lysed with RBC Lysis Buffer (eBioscience, San Diego, CA).
For osteoclastogenesis experiments, BM cells were plated at 4.3 3 10 5 cells per well in 48-well culture plates in the presence of M-CSF and RANKL (PeproTech Inc., Rocky Hill, NJ). Alkaline-phosphatasepositive stromal cells were fewer than 0.1% on day 5 of culture. No osteoclast differentiation was observed without RANKL. For inhibition of SYK kinase, 3-(1-Methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide (SYK inhibitor, Calbiochem, Darmstadt, Germany) was added to BM cells cultured with M-CSF (50 ng/ml) and RANKL (50 ng/ml). After 5 days, TRAP-positive cells with more than three nuclei were counted as osteoclasts.
For experiments with BM-derived macrophages, BM cells were cultured with a-MEM and 10% FBS for 2-12 hr, then nonadherent cells were cultured for 3 days in the presence of 50 ng/ml M-CSF. For measurements of TNF-a protein and transcript levels following stimulation with M-CSF, cells were starved for 2 hr in medium containing 0.1% FBS without M-CSF and with or without 10 mM U0126 (Cell Signaling Technology, Inc., Beverly, MA).
To block NF-kB signaling, nonadherent BM cells cultured for 3 days with 50 ng/ml M-CSF were harvested in M-CSF-free a-MEM containing 10% FBS and replated at a concentration of 3 3 10 5 cells per well in 96-well plates. The cells were incubated for 2 hr with or without 20 mM NEMO-binding domain peptide in a-MEM containing 10% FBS before being restimulated with 50 ng/ml M-CSF for an additional 36 hr. The sequence of the NEMO-binding domain peptide was drqikiwfqnrrmk wkk-TALDWSWLQTE (Jimi et al., 2004) .
Western Blotting
For studies of long-term effects of RANKL on osteoclastogenesis, 5.5 3 10 6 BM cells were cultured with M-CSF (50 ng/ml) in 6 cm culture plates for 2 days, then stimulated with RANKL (50 ng/ml) for an additional 3 days. To study short-term effects of RANKL stimulation of osteoclastogenesis, 5.5 3 10 6 BM cells were cultured with M-CSF (50 ng/ml) in 6 cm culture plates for 3 days, starved for 6 hr with 1% FBS and 1 ng/ml M-CSF, and then stimulated by RANKL (50 ng/ml). For studying effects of M-CSF stimulation of macrophages, 4.0 3 10 6 nonadherent BM cells were cultured with M-CSF (50 ng/ml) in 6 cm culture plates for 3 days, starved for 2 hr with M-CSF-free medium containing 0.1% FBS, and then stimulated by M-CSF (50 ng/ml). For determination of SH3BP2 in mutant tissues, spleens were snap frozen in liquid nitrogen and homogenized in lysis buffer. Cell lysates (for details, see Supplemental Data) were used for western blotting. Bands were detected using SuperSignal West Pico or Femto Chemiluminescent Substrate (Pierce Biotechnology Inc., Rockford, IL).
Peritoneal Macrophage Isolation
After euthanasia, 6 ml of DMEM were injected into peritoneal cavity and aspirated back. Peritoneal cells were pelleted by centrifugation, and 1 3 10 5 cells in 200 ml DMEM were plated in each well of a 96-well culture plate then incubated at 37 C for 1 hr. Adherent macrophages were further cultured in DMEM (10% FBS; for details, see Supplemental Data).
Flow Cytometry
Marrow cells were harvested from tibia and femur of 10-week-old mice. After RBC lysis, cells were stained with anti-CD11b (PE, clone: M1/70) antibodies and analyzed using FACSCalibur (BD Biosciences, San Jose, CA). Peritoneal cells were harvested from 6-to 10-week-old mice, stained with anti-CD11b (PE, clone: M1/70) and anti-F4/80 (PE-Cy5, clone: BM8) antibodies; permeabilized cells were stained with anti-TNF-a (FITC, clone: MP6-XT22) antibody and analyzed. All antibodies for FACS were from eBiosciences (San Diego, CA).
Retroviral Infection of BM-Derived Macrophages
HA-tagged wild-type and P416R Sh3bp2 cDNAs were subcloned into pMXs-IG vector (a gift from Prof. T. Kitamura). Transfection into Plat-E packaging cells was performed using FuGENE 6 (Roche, Alameda, CA). After 48 hr of transfection, supernatants were collected and used for infection. BM cells were cultured with M-CSF (50 ng/ml) for 48 hr followed by 24 hr in medium containing retrovirus and polybrene (8 mg/ml). Infection efficiency was normalized based on GFP expression. After infection, cells were stimulated with RANKL (50 ng/ml) for additional 72 hr, stained for TRAP (Sigma), or lysed for western blotting.
Fetal Liver Cell Transplantation
Fetal livers (E15.5) were dissociated in 10% FBS RPMI. After genotyping, 1 3 10 7 viable cells were injected intravenously into sublethally (250 cGy, 137 Cesium source) g-irradiated 4-to 5-week-old Rag1 null mice. After 6 weeks, successful transplantation was confirmed by the presence of abTCR-and B220-positive cells in peripheral blood. In recipient mice, the proportion of homozygous donor cells in M-CSF-dependent osteoclast precursor cells was about 70% as determined by semiquantitative genomic PCR.
Real-Time PCR for TNF-a Transcripts
Total RNAs were extracted using Trizol, and cDNAs were synthesized by Superscript II (Invitrogen). Real-time PCR was carried out with ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) using TaqMan PCR kit protocol (for details, see Supplemental Data). Expression levels of TNF-a transcripts were normalized to the number of 10 6 GAPDH transcripts.
Supplemental Data
Supplemental data include Supplemental Experimental Procedures and four figures and can be found with this article online at http:// www.cell.com/cgi/content/full/128/1/71/DC1/.
